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Abstract
Background: Osteoarthritis is associated with increased bone resorption and increased cartilage
degradation in the subchondral bone and joint. The objective of the present study was to determine
whether Tibolone, a synthetic steroid with estrogenic, androgenic, and progestogenic properties,
would have similar dual actions on both bone and cartilage turnover, as reported previously with
some SERMS and HRT.
Methods: This study was a secondary analysis of ninety-one healthy postmenopausal women aged
52–75 yrs entered a 2-yr double blind, randomized, placebo-controlled study of treatment with
either 1.25 mg/day (n = 36), or 2.5 mg/day Tibolone (n = 35), or placebo (n = 20), (J Clin Endocrinol
Metab. 1996 Jul;81(7):2419–22) Second void morning urine samples were collected at baseline, and
at 3, 6, 12, and 24 months. Urine CrossLaps® ELISA (CTX-I) and Urine CartiLaps® ELISA (CTX-II)
was investigated as markers of bone resorption and cartilage degradation, respectively.
Results: Tibolone significantly (P < 0.001) suppressed bone resorption by approximately 60%. In
contrast, no effect was observed on cartilage degradation.
Conclusion: These data suggest uncoupling of the bone and cartilage effects of the synthetic
steroid, Tibolone. Bone resorption was significantly decreased, whereas cartilage degradation was
unchanged. These effects are in contrast to those observed some SERMs with effects on both bone
and cartilage degradation. These effects may in part be described by the complicated pharmacology
of Tibolone on testosterone, estrogen and progesterone receptors.
Background
Osteoarthritis (OA) is the most common form of arthritis
[1]. One hallmark of the disease is progressive degenera-
tion of articular cartilage, generation of osteophytes and
subsequent joint space narrowing. This progression of dis-
ease may involve both bone and cartilage parameters,
which in some instances may be tightly coupled.
The relationship between bone and cartilage degradation
in OA is a complex. A apparent co-existence between the
two processes exists [2,3], although the cellular and
molecular mechanism remains to be further investigated
and identified [4]. Several groups have demonstrated an
accelerated incidence of OA in women following meno-
pause [5,6] which in part may be caused by increased
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bone resorption [7,8]. Studies investigating gender and
age as risk factors of developing OA indicate that OA
increases with age and women are at a higher risk than
men [9]., which supports the notion that sex hormones
are related to the incidence of OA. In addition, pre-clinical
studies in monkeys [10] and rats [11] have shown that
estrogen depletion results in increased bone turnover,
leading to altered subchondral bone structure and
decreased articular cartilage integrity.
In clinical settings a number of studies have provided evi-
dence for the coupling between bone and cartilage degra-
dation. A selective estrogen-receptor modulator (SERM)
was shown to protect against both bone and cartilage deg-
radation, by restoring turnover of both compartments to
pre-menopausal level during a 12 month period [12]. In
similar context, cartilage degradation was assessed in 384
postmenopausal women, and was found to be signifi-
cantly lower in women using hormone replacement ther-
apy (HRT) compared to control [6,12], and the cartilage
degradation was significantly higher in postmenopausal
women when compared to an age-matched group of pre-
menopausal women [6].
Tibolone is a synthetic steroid [(7-α,l7-α & 17-hydroxy-7-
methyl-l9-norpregn-5(1O)-en-20-yn-3-one, Org OD 14,
Livial, Organon, The Netherlands] with a combination of
estrogenic, androgenic, and progestogenic properties, is
capable of relieving climacteric symptoms [13-15] with
almost no stimulatory effect on the endometrium [16].
Tibolone is metabolized in the intestine and liver into 3
active metabolites: 3α- and 3β-hydroxy metabolites and
Δ4-7alpha-methylnorethisterone. The first two metabo-
lites bind to estrogen receptors, primarily ERα receptors,
and have estrogenic effects on bone, thermoregulatory
centers in the central nervous system, and the vagina [17-
19]. The Δ4-7alpha-methylnorethisterone metabolite
binds to the progesterone and androgen receptors. Tibo-
lone is primarily used to treat women with climacteric
complaints for whom bleeding is unacceptable, or who
have experienced side-effects during conventional HRT.
The estrogenic characteristics of tibolone imply an estro-
gen-like effect on bone as well, which have been docu-
mented and characterized previously [20,21].
Bone and cartilage degradation can be assed by biochem-
ical markers. Bone resorption by osteoclasts is for the
major part mediated by the protease cathespin K, which
results in the specific degradation fragment of collagen
type I, CTX-I [22,23]. CTX-I fragments have been used as
a surrogate measure of bone resorption for in vitro, pre-
clinical and clinical studies [22,24]. With respect to carti-
lage degradation, CTX-II, is a matrix metalloprotease
(MMP) generated fragment of collagen type II which is
predominately found in articular cartilage [25,26]. CTX-II
levels has been shown to predict structural progression of
osteoarthritis under several clinical settings [27].
As several lines of evidence suggest a tight coupling
between bone and cartilage turnover [28], and protective
effects of estrogens and some SERMs [28], the objective of
the present study was to determine whether Tibolone, a
synthetic steroid with estrogenic, androgenic, and pro-
gestogenic properties, would have similar dual actions on
both bone and cartilage turnover.
Methods
This study is a secondary analysis of the effects published
previously [21]. Ninety-one healthy postmenopausal
women aged 52–75 yrs entered a 2-yr double blind, rand-
omized, placebo-controlled study of treatment with either
1.25 mg/day (n = 36), or 2.5 mg/day tibolone (n = 35), or
placebo (n = 20) as previously described [21]. Second
void morning urine samples were collected at baseline,
and at 3, 6, 12, and 24 months. The biochemical marker
CTX-II was measured in urine by Urine CartiLaps® ELISA
(Nordic Bioscience A/S) as marker of cartilage degrada-
tion.
As described in the original publication, [21], after being
introduced thoroughly about the trial, participants gave
their informed consent to participate (Helsinki Declara-
tion II). The study was approved by the ethical committee
of Copenhagen County, Denmark.
Statistical analysis
To assess longitudinal changes, the values were calculated
for each person and expressed as the percentage of the ini-
tial baseline value. The data of the creatinine-corrected
values of CTXI and CTXII, and the relative changes were
logarithmically transformed to obtain normality and sym-
metry of variances. The trapezoidal method was applied
for calculation of the time-averaged mean change from
baseline. Analysis of variance (ANOVA) was used for com-
parison of baseline data between treatment groups. The
two-tailed Student's t-test was applied for pairwise com-
parison of data from the active treatment groups with pla-
cebo.
For all tests p < 0.05 was considered significant. All statis-
tical calculations were performed using the SAS software
package (release 9.1, SAS Institute Inc., Cary, NC, USA).
Results
Table 1 shows the baseline demographic data of the par-
ticipants within each treatment group who completed the
2-year study protocol as published previously [21]. The
group receiving 2.5 mg of tibolone was of slightly higher
height (p = 0.04). In all other aspects of age, weight, BMI,
years since menopause, and the biochemical markers ofBMC Musculoskeletal Disorders 2008, 9:153 http://www.biomedcentral.com/1471-2474/9/153
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urinary CTX-I and CTX-II there were no significant differ-
ences among the groups.
The effect of tibolone on bone resorption
Bone resorption was investigated by measurement of uri-
nary CTX-I during the 2 years of therapy every 3rd month
in the groups receiving 2.5 mg or 1.25 mg of tibolone, or
placebo. Tibolone inhibited bone resorption highly sig-
nificant with a plateau after 6, as seen in figure 1, upper
panel. The relative change from baseline in urinary CTX-I
during 2 years of therapy with 1.25 and 2.5 mg of tibolone
is presented in figure 1, lower panel. Values shown are
placebo-corrected time-averaged mean change during the
treatment period and given as mean ± 1 SEM. The level of
significance denotes difference from the placebo group:
*** p < 0.001. Data are modified with permission from
[21].
The effect of tibolone on cartilage degradation
Cartilage degradation was measured by measurement of
urinary CTX-II during the 2 years of therapy every 3rd
month in the groups receiving 2.5 mg or 1.25 mg of tibo-
lone, or placebo. Tibolone did not affect cartilage degra-
dation, as presented in figure 2, upper panel. The relative
change from baseline in urinary CTXII during 2 years of
therapy with 1.25 and 2.5 mg of tibolone is presented in
figure 2, lower panel. Values shown are placebo-corrected
time-averaged mean change during the treatment period
and given as mean ± 1 SEM.
Discussion
Experimental and clinical observations suggest that the
structural integrity of articular cartilage is dependent on
normal subchondral bone turnover, intact chondrocyte
function and ordinary biomechanical stresses [3,29-32].
Because there is an apparent inter-relationship between
the subchondral bone and the articular cartilage, interven-
tions with effect on bone turnover may possibly have sec-
ondary or direct effects on cartilage turnover.
The presented data suggest that bone resorption can be
strongly attenuated without the secondary positive effects
on cartilage degradation. In fact, a trend toward increased
cartilage degradation that may have become statistical sig-
nificant if more samples had been available was observed.
These data indicate that the tight coupling between bone
and cartilage metabolism can be disassociated under
some circumstances. This uncoupling is an important dif-
ference compared to that other estrogen like molecules
and SERMS that have displayed protective effects on both
bone and cartilage degradation. In the present study the
observed effect size of 2.5 mg of Tibolone was an increase
of 19% [95% confidence interval -17%;+70%] in CTXII.
This is in contrast to other interventions that all have
shown a decrease in CTXII, e.g. risedronate a decrease of
30% [33,34], estrogen replacement therapy a decrease of
25% [35], strontium ranelate a decrease of 15–20% [36]
and levormeloxifene with a decrease of 50% [12].
Bone and OA
An increasing amount of attention has been devoted to
the role of the bone in the pathogenesis of osteoarthritis.
Subchondral bone sclerosis, alterations in the trabecular
structure, lesions (previously called development of bone
marrow edema) and osteophytes are important features of
the pathology of OA [2,10,29,37-39]. The present under-
standing remains on an observational level, in which an
increasing range of experimental evidence is emerging. In
support of the important role of bone turnover in the
pathogenesis of OA, several independent lines of experi-
mental evidence are found [3,29-32]. In brief, examina-
tions of peri-articular bone in knees and hips with OA
have confirmed that the subchondral bone is abnormal in
OA joints, which altered trabecular structure, sclerosis of
the subchondral plate [40], as well increased bone turno-
ver [41,42]. Cross-sectional studies have also established
that women with advanced knee or hip OA have a higher
bone mineral density (BMD) near or at the site of joint OA
[43]. Plausible proof of a link between bone and cartilage
recently came from an animal model of OA, where exten-
sive inhibition of bone resorption resulted in a 50%
decrease in cartilage pathology score assessed by Mankin
score [29,38]. In addition, accelerated bone turnover has
in both traumatic and estrogen deficiency models (ova-
riectomy (OVX)) been shown to augment articular carti-
lage erosion [7,11,12,44,45], in which increased bone







Age (yrs) 68.3 (6.0) 66.5 (7.0) 64.0 (6.7)
YSM (yrs) 20 (6.2) 19.6 (6.1) 17.5 (6.5)
Height (cm) 158.5 (5.3) 159.7 (5.9) 162.9 (6.1)
Weight (kg) 61.8 (6.8) 62.5 (9.5) 61.1 (6.8)
BMI (kg/m2) 24.7 (3.2) 24.5 (3.4) 23.1 (2.8)
aCTXI (μg/mmol) 0.26 (0.18–0.37) 0.32 (0.21–0.49) 0.31 (0.22–0.45)
aCTXII (μg/mmol) 0.13 (0.08–0.26) 0.17 (0.09–0.32) 0.13 (0.07–0.24)BMC Musculoskeletal Disorders 2008, 9:153 http://www.biomedcentral.com/1471-2474/9/153
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Bone resorption. Upper panel: Urinary CTXI during 2 years of therapy in the groups receiving 2.5 mg, 1.25 mg of tibolone, or  placebo Figure 1
Bone resorption. Upper panel: Urinary CTXI during 2 years of therapy in the groups receiving 2.5 mg, 1.25 mg 
of tibolone, or placebo. Values shown are geometric mean ± 1 SEM. B. Lower panel: Mean relative change from baseline in 
urinary CTXI during 2 years of therapy with 1.25 and 2.5 mg of tibolone. Values shown are placebo-corrected time-averaged 
mean change during the treatment period and given as mean ± 1 SEM. The level of significance denotes difference from the pla-
cebo group: *** p < 0.001. Modified with permission from [21].BMC Musculoskeletal Disorders 2008, 9:153 http://www.biomedcentral.com/1471-2474/9/153
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Cartilage degradation: Upper panel: Urinary CTXII (lower panel) during 2 years of therapy in the groups receiving 2.5 mg, 1.25  mg of tibolone, or placebo Figure 2
Cartilage degradation: Upper panel: Urinary CTXII (lower panel) during 2 years of therapy in the groups 
receiving 2.5 mg, 1.25 mg of tibolone, or placebo. Values shown are geometric mean ± 1 SEM. Lower panel: Mean rela-
tive change from baseline in urinary CTXII during 2 years of therapy with 1.25 and 2.5 mg of tibolone. Values shown are pla-
cebo-corrected time-averaged mean change during the treatment period and given as mean ± 1 SEM. Levels did not reach 
significance.BMC Musculoskeletal Disorders 2008, 9:153 http://www.biomedcentral.com/1471-2474/9/153
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resorption alone results in increased articular cartilage
damage [10,37,46].
Thereby, interventions that may positively affect bone
turnover, may in theory have secondary positive effects on
progression of OA. The present data strongly suggest that
these processes can be uncoupled. This might in part be
mediated through the androgenic properties of tibolone,
as androgens in contrast to that of estrogens might have
deleterious effects on cartilage health [45]. However the
effects of androgens and the direct on articular cartilage
compared to that of estrogens needs additional attention.
Estrogen and OA
The putative positive of some estrogens of cartilage health
may both be though indirect and direct effects on carti-
lage. Estrogens are anti-resorptives that directly and indi-
rectly attenuates osteoclastogenesis and osteoclastic
resorption [47]. At the same time, chondrocytes express
estrogen receptors, and respond to estrogen [11,48-52].
The positive long-term beneficial effect of estrogen for
prevention of OA was recently demonstrated in 180
female cynomolgus monkeys [10], receiving estrogen
replacement therapy (ERT) treatment for 3 years. Signifi-
cant less cartilage lesions of OA were seen in the ERT
group compared to the control group. In addition, several
preclinical models have provided evidence for protective
effects of estrogen [11,12,46].
In clinical settings a number of studies have suggested
positive effects on cartilage degradation. A SERM was
shown to protect against both bone and cartilage degrada-
tion [53], and cartilage degradation and was found to be
significantly lower in women using hormone replacement
therapy (HRT) compared to control [6,12,54], and the
cartilage degradation was significantly higher in postmen-
opausal women when compared to an age-matched group
of pre-menopausal women. These data are in alignment
with the recent analysis from the WHI studies, which doc-
umented that women taking estrogen had 45% less total
joint surgery compared to of placebo [55].
However in the present study Tibolone did not result in
secondary positive effects on cartilage degradation. This
may in part be described by the complicated pharmacol-
ogy of Tibolone on testosterone, estrogen and progester-
one receptors. This is in contrast to others SERM and
estrogen like molecules that to a much larger extent is
selective for the estrogen receptor.
Limitations of the current study
The present study has some limitations. Cartilage degra-
dation was evaluated by the biochemical markers u-CTX-
II. Levels of u-CTX-II have been shown to correlate with
cartilage damage in both animal models and clinical trials
[7,11,27,56], however long term randomized clinical tri-
als studies are needed to further investigate and document
the putative positive effects of estrogens on the pathogen-
esis of osteoarthritis.
Biochemical markers of cartilage degradation measured in
the systemic fluids, serum and urine, are the net results of
the biological activity of all joints and tissues in which col-
lagen type II present. CTX-II is generated by MMP activity
[57] have been shown to be produced by catabolically
stimulated articular cartilage, and present in damaged
articular cartilage [25,56]. However, CTX-II may in addi-
tion be generated by the cartilage of non-synovial joints.
The main contributors of cartilage degradation biomark-
ers have been shown to be; knees, hips, hands, vertebral
facet joints in addition to spinal disc degeneration (DD)
[58,59]. In addition, a smaller contribution of CTX-II may
originate from the calcified cartilage in the subchondral
bone area [28]. The contribution of each cartilage com-
partment to the total pool of cartilage degradation meas-
ured is important to further understand, for the
interpretation of the effect on the total pool of any bio-
chemical marker. Some insights into the relative contribu-
tion of the different joints to the total amount of CTX-II
have been provided [58]. CTX-II was shown to be related
to the number of joint affected, evaluated by radiological
OA, in which generalised resulted in an approximately
100% increase in CTX-II [58]. In addition, CTX-II was very
recently shown to predict medial knee articular cartilage
loss evaluated by quantitative MRI [60]. With respect to
the current study, each compartment may have contrib-
uted differently to the pool of CTX-II, also in response to
therapy. Further research is needed to understand the
effects of estrogen and estrogen related compounds on the
individual joints.
The analysis was performed by re-analysis on stored sam-
ples, which to some extend may have influenced that
measurements. However, in house data suggest that u-
CTX-II is stable for more than 3 years under the appropri-
ate conditions.
Conclusion
In summary, we describe for the first time that anti-resorp-
tive treatments can result in an uncoupling of the bone
and cartilage protective effects, measured by biochemical
markers and the limitation associated with those. These
findings may result in questioning of the coupling
between bone and cartilage, and whether they indeed are
separate or coupled processes.
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